Instructions for Authors 2018

General Policy. ANTIcancer RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTIcancer RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTIcancer RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html
In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   - The Instructions to Authors must be followed in every detail.
   - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   - Results given in figures should not be repeated in tables.
   - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by… authors, year).
   - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
   - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   - they do not fall within the journal's policy.
   - they do not follow the instructions for authors.
   - language is unclear.
   - results are not sufficient to support a final conclusion.
   - results are not objectively based on valid experiments.
   - they repeat results already published by the same or other authors before the submission to AR.
   - plagiarism is detected by plagiarism screening services.
   (Rejection rate (2016): 66%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org.

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
   (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.

The principal aim of IN VIVO is to provide prompt open online publication for accepted articles, generally within 1-2 months from final acceptance.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IAR WEBSITES: www.iiar-anticancer.org and www.iiarjournals.org

International Journal of Experimental and Clinical Pathophysiology and Drug Research

Published bimonthly by the International Institute of Anticancer Research

Available online only and open access with Stanford University HighWire Press

Selection of Recent Articles


Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. S.A. ERICH, F. CONSTANTINO-CASAS, J.M. DOBSON, E. TESKE (Utrecht, The Netherlands; Cambridge, UK)

Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts. R.A. VAN NOORD, T. MACDERMOT, E. HALL (Ann Arbor, MI, USA)

Re-evaluation of Culture Condition of PC12 and SH-SYSY Cells Based on Growth Rate and Amino Acid Consumption. H. SAKAGAMI, R. SUZUKI, Y. SHIRATAKI, S. IWAMA, M. NAKAGAWA, H. SUZUKI, K. TANAKA, N. TAMURA, H. TAKASHIMA (Sakado, Japan)

Clinical Impact of Rest Dual-Energy Computed Tomography Myocardial Perfusion in Patients with Coronary Artery Disease. S. BAUMANN, et al. (Mannheim, Germany)

Effects of 2,3-Bis(4-hydroxyphenyl)-propionitrile on Induction of Polyovular Follicles in the Mouse Ovary. T. SATO, H. KIM, H. KAKUTA, T. IGUCHI (Yokohama, Japan)

Cell-cycle Checkpoints and Aneuploidy on the Path to Cancer. E.S. WENZEL, A.T.K. SINGH (Kenoshwi, WI, USA)


Proiling Neutrophil-to-Lymphocyte Ratio Changes in Response to Nucleoside Analog Therapy for Chronic Hepatitis B Infection. M. MARALLAG, A. PATEL, M. CHOI, M.N. WONG, A.B. SEETHARAM (Phoenix; Tempe, AZ, USA)

Comparison of the Grip Strength Using the Martin-Vigorimeter and the JAMAR-Dynamometer: Establishment of Normal Values. S. NEUMANN, S. KWISDA, C. KREITKE, R. GAULKE (Hannover; Hamburg, Germany; Zurich, Switzerland)

Role for Neutrophil Extracellular Traps (NETs) and Platelet Aggregation in Early Sepsis-induced Hepatic Dysfunction. K. SAKURAI, T. MIYASHITA, et al. (Ishikawa, Japan; Baltimore, MD, USA)

Netrin-4 Promotes Differentiation and Migration of Osteoblasts. Y. ENOKI, T. SATO, S. KOKUBU, N. HAYASHI, T. IWATA, M. YAMATO, M. USUI, M. MATSUMOTO, T. TOMODA, W. ARIYOSHI, T. NISHIHARA, T. YODA (Saitama; Fukuoka; Tokyo, Japan)

Early PET-CT After Stereotactic Radiotherapy for Stage I Non-small-cell Lung Carcinoma Is Predictive of Local Control. M. TYRAN, N. CHARRIE, J. DARREON, A. MADROSZYK, A. TALLET, N. SALEM (Marseille, France)

**Selection of Recent Articles**

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets. U.H. WEIDLE, S. DICKOFF, C. HINTERMAIR, G. KOLLMORGEN, F. BIRZEL, U. BRINKMANN (Penzberg; Munich, Germany; Basel, Switzerland)

Transcriptomic Profiling of MDA-MB-231 Cells Exposed to Boswellia Serrata and 3-O-Acetyl-B-Boswellic Acid; ER/UPR Mediated Programmed Cell Death. M.A. ELIZABETH, L.A. CHARLES, SOLIMAN FA. KARAM (Tallahassee, FL, USA)

Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer. L. BASSARO, S.J. RUSSELL, E. PASTWA, S.A. SOMIARI, R.I. SOMIARI (Johnstown; Windber, PA, USA)


Regulation of β-Catenin Phosphorylation by PR55β in Adenoid Cystic Carcinoma. K. ISHIBASHI, K. ISHII, G. SUGIYAMA, Y. KAMATA, A. SUZUKI, W. KUMAMARU, O. OHYAMA, H. NAKANO, T. KIYOSHI, T. SUMIDA, T. YAMADA, Y. MORI (Fukuoka, Japan)

Admixture Mapping Links RACGAP1 Regulation to Prostate Cancer in African Americans. B.D. WILSON, L.J. RICKS-SANTI, T.E. MASON, M. ABBAS, R.A. KITTLES, G.M. DUNSTON, Y.M. KANAAN (Washington, DC; Hampton, VA; Duarte, CA, USA)

Consistent Involvement of Chromosome 13 in Angiolipoma. I. PANAGOPoulos, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (Oslo, Norway)

Analysis of K-Ras Interactions by Biotin Ligase Tagging. C. RITCHIE, A. MACK, L. HARPER, A. ALFADHLLI, P.J.S. STORK, X. NAN, E. BARKLIS (Portland, OR, USA)

CYP3A4 Gene Is a Novel Biomarker for Predicting a Poor Prognosis in Hepatocellular Carcinoma. R. ASHIDA, Y. OKAMURA, K. OSHIMA, Y. KAKUDA, K. UESAKA, T. SUGIURA, T. ITO, Y. YAMAMOTO, T. SUGINO, K. URAKAMI, M. KUSUHARA, K. YAMAGUCHI (Shizuoka; Tokyo, Japan)
Subscription Order Form 2018

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 38 (2018).
   Annual subscription rates (2018): Institutional, US$ 1898.00 online, US$ 2277.00 online & print; Personal, US$ 897.00 online; US$ 1277.00 online & print; Prices include rapid delivery and insurance.
   2018 online subscriptions include free online access to vol. 24 (2004) - 37 (2017).

☐ Please send me the following previous volumes (1-37) at 50% discount on the above rates:

☐ Please invoice.

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ................................................................................................................................................................
................................................................................................................................................................................................
Tel: .........................................................................................................................................................................................
Fax: ..................................................................................................................................................................................
Signature: ...........................................................................................................................................................................
Date: .................................................................................................................................................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2018 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2018 on a basis of priority and availability. Effective from January to December 2018).

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2018

☐ I am one of the authors of the article published in Anticancer Research Vol..........., pp. ............, year ............

☐ Please enter my personal subscription to Anticancer Research 2018 (Volume 38) at the special Author’s rate of US$ 465.00 (print or online).

☐ Please send me previous Volume No(s) ......................... at US$ 224.00 (print) per volume.

☐ Please send me an invoice.

Prices include rapid delivery and insurance.

Name and address: ................................................................................................................................................................
................................................................................................................................................................................................
Tel-Fax: ..................................................................................................................................................................................
e-mail: ..........................................................................................................................................................................
Date and signature: ................................................................................................................................................................

Your link to the essential information on cancer research published in the last 37 years.
- 1981-2017
- 37 volumes
- over 131,300 pages
- over 19,300 original articles
- 993 reviews
- over 90,000 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes
- Rapid publication
- No fees for language and style corrections
Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial. T. SPRAVE, V. VERMA, R. FÖRSTER, I. SCHLAMPP, K. HEES, T. BRUCKNER, T. BOSTEL, R. EL SHAFIE, N.H. NICOLAY, J. DEBUS, H. RIEF (Heidelberg; Dortmund; Freiburg, Germany; Pittsburgh, PA, USA; Zurich, Switzerland) ................................................................. 4953

Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial. T. SPRAVE, V. VERMA, R. FÖRSTER, I. SCHLAMPP, T. BRUCKNER, T. BOSTEL, R.A. EL SHAFIE, N.H. NICOLAY, J. DEBUS, H. RIEF (Heidelberg; Freiburg, Germany; Pittsburgh, PA, USA; Zurich, Switzerland) ................. 4961

Controlling Nutritional Status (CONUT) Score Is a Prognostic Marker in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy. N. DAITOKU, Y. MIYAMOTO, R. TOKUNAGA, Y. SAKAMOTO, Y. HIYOSHI, M. IWATSUKI, Y. BABA, S. IWAGAMI, N. YOSHIDA, H. BABA (Kumamoto, Japan) .............. 4883

CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy. V. CIARAVINO, N. CARDORI, R. DE ROBERTIS, P. CAPELLI, D. MELISI, F. SIMIONATO, G. MARCHEGIANI, R. SALVIA, M. D’ONOFRIO (Verona, Italy) ........................................................................................................................................ 4889

Brainstem Glioblastoma Multiforme in a Patient with NF1. J.T. FORTUNATO, B. REYS, P. SINGH, E. PAN (Detroit, MI; Dallas, TX, USA) ........................................................................................................................................................................... 4897

The Effect of Roux-en-Y Reconstruction on Type 2 Diabetes in the Early Postoperative Period. H. KASHIHARA, M. SHIMADA, K. YOSHIKAWA, J. HIGASHIJIMA, T. MIYATANI, T. TOKUNAGA, M. NISHI, C. TAKASU (Tokushima, Japan) ..................................................... 4901

OPG, OPN, EGF and VEGF Levels at Individual Breslow Score Stages in Malignant Melanoma. I. TRESKOVA, O. TOPOLCAN, J. WINDRICH OVA, V. SIMANEK, D. SLOUKA, V. TRESKA, R. KUCERA (Pilsen, Czech Republic) ........................................................................................................................................................................................................... 4907

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience. A. SBRANA, E. BIASCO, F. PAOLIERI, E. PALESANDRO, C. CASERTA, R. IACOVELLI, B. DETTI, D. SANTINI, A. MOSCA, F. MORELLI, G. FORNARINI, U. DE GIORGI, C. MASINI, L. GALLI (Pisa; Livorno; Terni; Verona; Florence; Rome; Novara; San Giovanni Rotondo; Genoa; Meldola; Reggio Emilia, Italy) ........................................................................................................................................ 4913


Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer. T. FUJI, K. YANAI, S. TOKUDA, Y. NAKAZAWA, S. KUROZUMI, S. OBAYASHI, R. YAJIMA, T. HIRAKATA, K. SHIRABE (Gunma, Japan) ........................................................................................................................................................................................................... 4927


A Bi-national Analysis of 252 Pancreatic Resections for Chronic Pancreatitis with Regard to Incidental Carcinoma Sequence and Overall Postoperative Outcome. T. MALINKA, F. KLEIN, T.L. THU, C.S. RÖSCH, H. WUNDSAM, M. BIEBL, J. PRATSCHKE, M. BAHRA, R. FÜGGER (Berlin, Germany; Linz, Austria).................................................................................................................................................................................................................. 4947


Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma. Y.-M. LEE, M.-K. YEO, I.-O. SEONG, K.-H. KIM (Cheonan; Daejeon, Republic of Korea) .......................................................... 4819


Predicting the Ambulatory Status of Patients Irradiated for Metastatic Spinal Cord Compression (MSCC) from Head-and-neck Cancer. D. RADES, C. STAACKMANN, S. JANSSSEN (Lübeck; Hannover, Germany) ............... 4833

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. L. ROSSI, C. BIAIONI, A. MCCARTNEY, E. MORETTI, M. PESTRIN, G. SANNA, E. RISI, L. MALORNI, A. DI LEO, L. BIGANZOLI (Prato, Italy; Bellinzona; Lugano, Switzerland) ............................................................ 4839

Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree. W. LIU, D. ZHANG, S.A. TAN, X. LIU, J. LAI (Changsha, PR China; Gainesville, FL, USA) ............................................................................ 4847

Cost-Effectiveness of Carbon Ion Radiation Therapy for Skull Base Chordoma Utilizing Long-Term (10-Year) Outcome Data. T. SPRAVE, V. VERMA, F. STERZING, T. BRUCKNER, K. HEES, B. LAND, O. JÄKEL, K. HERFARTH, J. DEBUS, M. UHL (Heidelberg; Kempten; Dortmund; Mannheim, Germany; Omaha, NE, USA) .................................................. 4853


Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer. A. PARASHKEVOVA, J. SEHOULI, R. RICHTER, D. DIMITROVA, E.I. BRAICU, M.Z. MUALLEM (Berlin, Germany) ................................................................................................................................. 4865

Predictors for High Microsatellite Instability in Patients with Colorectal Cancer Fulfilling the Revised Bethesda Guidelines. K. ARAKAWA, K. HATA, K. KAWAI, T. TANAKA, T. NISHIKAWA, K. SASAKI, Y. SHUNO, M. KANEKO, M. HIYOSHI, S. EMOTO, K. MURONO, H. NOZAWA (Tokyo, Japan) .................................................................................................................................................. 4871

Contents continued on the preceding page
Clinical Studies

Overexpression of FGFR3 in HPV-positive Tonsillar and Base of Tongue Cancer Is Correlated to Outcome. C. BERSANI, L. HAEGGBLOM, R.G. URSU, S.E. GIUSCA, L. MARKLUND, T. RAMQVIST, A. NÄSMAN, T. DALIANIS (Stockholm, Sweden; Iasi, Romania) ................................................................. 4683


Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs. S. WATANABE, O. YAMAGUCHI, A. MASUMOTO, Y. MAENO, Y. KAWASHIMA, O. ISHIHOTO, S. SUGAWARA, H. YOSHIZAWA, T. KIKUCHI, T. NUKIWA, K. KOBAYASHI (Niigata; Saitama; Sendai; Tokyo, Japan) .......................................................................................................................... 4699


Tumor Budding Versus Mismatch Repair Status in Colorectal Cancer – An Exploratory Analysis. M. KARLBERG, K. STENSTEDT, M. HALLSTRÖM, P. RAGNHAMMAR, C. LENANDER, D. EDLER (Stockholm, Sweden) .................................................................................................................... 4713


The Frequency and Prognostic Value of Neutrophilia in Chronic Lymphocytic Leukemia. I. LEVY, Z. VADASZ, A. POLIAK, T. TADMOR (Haifa; Jerusalem, Israel) .................................................................................................................. 4731

Preoperative Prognostic Nutritional Index Predicts Long-term Outcome in Gastric Cancer: A Propensity Score-matched Analysis. N. HIRAHARA, Y. TAJIMA, Y. FUJI, T. YAMAMOTO, R. HYAKUDOMI, T. TANIURA, S. KAJI, Y. KAWABATA (Shimane, Japan) .................................................................................................................. 4735

The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER+/HER2–Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index. K. MOKBEL, U. WAZIR, A. WAZIR, A. KASEM, K. MOKBEL (London, UK; Albany, NY, USA) .................. 4747

Chitinase-3-like Protein 1 (YKL-40) Expression in Squamous Cell Skin Cancer. J. SALOMON, A. PIOTROWSKA, Ł. MATUSIAK, P. DZIEGIEL, J.C. SZEPETOWSKI (Wrocław, Poland) .................................................................................................................. 4753


Relationship Among Tumor Attenuation Value of Pre-contrast Computed Tomography (CT), Washout Rate and Constituent Cells in Adrenal Adenoma: Proposition of a New Approach for Diagnosing Adrenal Adenoma on Dynamic CT. A. NISHIE, M. SUGIMOTO, Y. ASAYAMA, K. ISHIHAMA, Y. USHIJIMA, Y. TAKAYAMA, D. OKAMOTO, N. FUJITA, A. YOKOMIZO, K. TATSUGAMI, H. HONDA (Fukuoka, Japan) ................................................................. 4767

Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel. E.S. KENAN, M. FRIGER, D. SHOCHAT-BIGON, H. SCHAYEK, R. BERNSTEIN-MOLHO, E. FRIEDMAN (Beer Sheba; Tel-Hashomer; Tel-Aviv, Israel) ................................................................. 4557


Exocyclic Sulfur and Selenoorganic Compounds Towards Their Anticancer Effects: Crystallographic and Biological Studies. E. ŻESŁAWSKA, A. KINCSES, V. UNGER, V. TÓTH, G. SPENGLER, W. NITEK, W. TEICHMAN (Kraków, Poland; Szeged, Hungary) ........................................................................................................ 4577

Morphological Analysis of Amoeboid–Mesenchymal Transition Plasticity After Low and High LET Radiation on Migrating and Invading Pancreatic Cancer Cells. A. FACOETTI, C. DI GIOIA, F. PASI, R. DI LIBERTO, F. CORBELLA, R. NANO, M. CIOCCA, F. VALVO, R. ORECCHIA (Pavia; Milan, Italy) ......................................... 4585


 Tight Junction Protein 1 Dysfunction Contributes to Cell Motility in Bladder Cancer. K.-W. TSAI, W.-T. KUO, S.-Y. JENG (Kaohsiung; Pingtung; Taipei, Taiwan, ROC) .......................................................................................... 4607

Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells. P. WIŃSKA, K. SKIERKA, E. LUKOWSKA-CHOJNACKA, M. KORONKIEWICZ, J. CIEŚLA, M. BRENER (Warsaw, Poland) ........................................................................................................... 4617

Tissue Rebuilding During Spontaneous Regression of Melanoma in the Melanoma-bearing Libechov Minipig. D. PLANSKA, J. KOVALSKA, J. CIZKOVA, V. HORAK (Prague; Libechov, Czech Republic) ......................................................... 4629

Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. K. SHIMIZU, R. OKITA, S. SAISHO, A. MAEDA, Y. NOJIMA, M. NAKATA (Kurashiki, Japan) .................................................................................................................. 4637

Particle Stability During Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC). A. MIKOLAJCZYK, V. KHOSRAWIPOUR, J. SCHUBERT, H. CHAUDHRY, A. PIGAZZI, T. KHOSRAWIPOUR (Wroclaw, Poland; Dortmund, Germany; Irvine, CA, USA) .................................................................................... 4645

Evaluation of Injectable Chitosan-based Co-crosslinking Hydrogel for Local Delivery of 188Re-LIPO-DOX to Breast-tumor-bearing Mouse Model. F.-Y.J. HUANG, C.-C. HUNG, C.-W. CHANG, J.-H. CHAO, B.-T. HSIEH (Hsinchu; Taichung, Taiwan, ROC) ............................................................................................................. 4651

Biomarkers of Oxidative Stress Associated with the Risk of Potentially Malignant Oral Disorders. T. SENGHORE, Y.-F. LI, F.-C. SUNG, M.-H. TSAI, C.-H. HUA, C.-S. LIU, R.-J. HUANG, C.-C. YEH (Taipei; Taichung, Taiwan, ROC; Banjul, Gambia) ................................................................................................. 4661


Contents continued on the preceding page
CD133 Expression as a *Helicobacter pylori*-independent Biomarker of Gastric Cancer Progression. R. HOWARD, S. AL DIFALHA, J. PIMENTO, J. MEJIA, H. ENDERLING, A. GIULIANO, D. COPPOLA (Tampa, FL, USA; Valle del Cauca, Colombia) .................................................................

Quantitative Structure–Cytotoxicity Relationship of Pyrano[4,3-b]chromones. J. NAGAI, H. SHI, Y. KUBOTA, K. BANDOW, N. OKUDAIRA, Y. UESAWA, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, K. TAKAO, Y. SUGITA (Tokyo; Saitama, Japan; Shanghai, PR China) .................................................................

Quantitative Structure–Cytotoxicity Relationship of 3-(N-Cyclicamino)chromone Derivatives. H. SHI, J. NAGAI, T. SAKATSUME, K. BANDOW, N. OKUDAIRA, Y. UESAWA, H. SAKAGAMI, M. TOMOMURA, A. TOMOMURA, K. TAKAO, Y. SUGITA (Shanghai, PR China; Saitama; Tokyo, Japan) .................................................................

Antineoplastic Actions of Cinnamic Acids and Their Dimers in Breast Cancer Cells: A Comparative Study. M. HUNKE, W. MARTINEZ, A. KASHYAP, T. BOKOSKIE, M. PATTABIRAMAN, S. CHANDRA (Kearney, NE, USA) .................................................................................................................................

Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the β-catenin Pathway. A. BOMMAREDDY, K. KNAPP, A. NEMETH, J. STEIGERWALT, T. LANDIS, A.L. VANWERT, H.P. GORJIJAVOLU, C. DWIVEDI (Wilkes-Barre, PA; Dayton, NJ; Brookings, SD, USA) .................................................................

Intratumoral Accumulation and Clonal Expansion May Not Be Decisive for Rejection of Allogeneic Tumors by CD8+ T-Lymphocytes. J. JURŠENAITĖ, I. GIRKONTAITĖ, A. ŠIAURYS, M. MAURICAS, D. CHARACIEJUS (Vilnius, Lithuania) .................................................................................................................................

Cannabinoid Receptor-1 Up-regulation in Azoxymethane (AOM)-treated Mice After Dietary Treatment with Quercetin. V. TUTINO, V. DE NUNZIO, A. TAFARO, G. BIANCO, I. GIGANTE, M.P. SCAVO, R. D’ALESSANDRO, M.G. REFOLO, C. MESSA, M.G. CARUSO, M. NOTARNICOLA (Bari, Italy) .................................................................................................................................

Development and Evaluation of Talazoparib Nanoemulsion for Systemic Therapy of BRCA1-mutant Cancer. N.K. MEHRA, R.R. TEKMAL, S. PALAKURTHI (Kingsville; San Antonio, TX, USA) .................................................................................................................................

Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL. K. OKUBO, A. SATO, M. ISONO, T. ASANO, T. ASANO (Tokorozawa, Japan) .................................................................................................................................

Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. T. MASUDA, Y. SHINDEN, M. NODA, H. UE0, Q. HU, Y. YOSHIKAWA, Y. TSURUDA, Y. KURODA, S. ITO, H. EGUCHI, S. OHNO, K. MIMORI (Beppu; Fukuoka; Tokyo, Japan) .................................................................................................................................


A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel. K. TOGASHI, M. OKADA, M. YAMAMOTO, S. SUZUKI, T. SANOMACHI, S. SEINO, H. YAMASHITA, C. KITANAKA (Yamagata, Japan) .................................................................................................................................


Modulation of Exposure to Static Magnetic Field Affects Targeted Therapy of Solid Tumors In Vivo. D. GELLICH, U. SCHMIDTMAYER, J. ECKRICH, J. HAGEMANN, S. BECKER, S. STRIETH (Munich; Hannover; Mainz, Germany) .................................................................................................................................